Vaccine model of antiphospholipid syndrome induced by tetanus vaccine

Successful induction of antiphospholipid syndrome (APS) in two different non-autoimmune prone mouse strains, BALB/c and C57BL/6, was achieved by tetanus toxoid (TTd) hyperimmunization using different adjuvants (glycerol or aluminium hydroxide), and different adjuvant pretreatments (glycerol or Complete Freund’s Adjuvant (CFA)). APS had different manifestations of reproductive pathology in BALB/c and C57BL/6 mice: fetal resorption (as a consequence of extreme T-cell activation obtained in the course of pretreatment), and lowering of fecundity (as a consequence of polyclonal B-cell stimulation), respectively. In BALB/c mice fetal resorption coincided with glycerol and CFA pretreatments, while in C57BL/6 mice lowering of fecundity was most obvious in CFA-pretreated mice immunized with TTd in aluminium hydroxide. Both molecular mimicry and polyclonal B-cell activation occur in APS induction, with molecular mimicry effects being dominant in BALB/c mice, and polyclonal cell activation being dominant in C57BL/6 mice. Confirmation of molecular mimicry effects, which in the condition of T-cell stimulation generated fetal resorptions in the BALB/c strain, was achieved by passive infusion of monoclonal antibody (MoAb) T-26 specific for TTd and anti-β2-glycoprotein I obtained after TTd hyperimunization. High polyclonal B-cell activation in C57BL/6 mice prevented fetal resorption but induced fecundity lowering, as was the case in passive administration of MoAb T-26 in this mouse strain. Passive infusion of anti-idiotypic MoAb Y7 into C57BL/6 mice induced fetal resorptions and confirmed the above suggestion on the protective role of polyclonal B-cell stimulation in fetal resorptions.

[1]  Marijana Stojanović,et al.  Induction of decreased fecundity by tetanus toxoid hyper-immunization in C57BL/6 mice depends on the applied adjuvant , 2012, Innate immunity.

[2]  Marijana Stojanović,et al.  Induction of APS after TTd Hyper‐Immunization has a Different Outcome in BALB/c and C57BL/6 Mice , 2011, American journal of reproductive immunology.

[3]  R. Cano,et al.  Trypanosoma cruzi antigen immunization induces a higher B cell survival in BALB/c mice, a susceptible strain, compared to C57BL/6 B lymphocytes, a resistant strain to cardiac autoimmunity , 2011, Medical Microbiology and Immunology.

[4]  I. Živković,et al.  Network connectivity is shown to change in C57BL/6 mice during a continuing immune response subsequent to tetanus toxoid hyperimmunization. , 2010, Biological research.

[5]  Y. Shoenfeld.  Infections, vaccines and autoimmunity , 2009, Lupus.

[6]  T. Avčin,et al.  Vaccination of healthy subjects and autoantibodies: from mice through dogs to humans , 2009, Lupus.

[7]  Marijana Stojanović,et al.  The context of tetanus toxoid application influences the outcome of antigen‐specific and self‐directed humoral immune response , 2009, Microbiology and immunology.

[8]  I. Živković,et al.  ORIGINAL ARTICLE: Murine Monoclonal Antibody 26 Raised Against Tetanus Toxoid Cross‐Reacts with β2‐Glycoprotein I: Its Characteristics and Role in Molecular Mimicry , 2008, American journal of reproductive immunology.

[9]  U. Steinhoff,et al.  TLR-Activated B Cells Suppress T Cell-Mediated Autoimmunity1 , 2008, The Journal of Immunology.

[10]  P. Meroni.  Pathogenesis of the antiphospholipid syndrome: an additional example of the mosaic of autoimmunity. , 2008, Journal of autoimmunity.

[11]  M. Fresno,et al.  Spleen B cells from BALB/c are more prone to activation than spleen B cells from C57BL/6 mice during a secondary immune response to cruzipain. , 2007, International immunology.

[12]  S. Rahgozar,et al.  Current concepts on the pathogenesis of the antiphospholipid syndrome. , 2007, Blood.

[13]  L. Morel,et al.  Role of B-1a cells in autoimmunity. , 2006, Autoimmunity reviews.

[14]  J. Brewer.  (How) do aluminium adjuvants work? , 2006, Immunology letters.

[15]  S. Tsai,et al.  Hepatitis C virus infection‐related Type 1 diabetes mellitus , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[16]  D. Vergani,et al.  Non-organ-specific autoantibodies in hepatitis C virus infection: do they matter? , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  Y. Shoenfeld,et al.  Vaccines in the 21st century: the genetic response and the innocent bystander. , 2005, Autoimmunity reviews.

[18]  Harold F. Stils.  Adjuvants and Antibody Production: Dispelling the Myths Associated with Freund's Complete and Other Adjuvants , 2005 .

[19]  H. Stills.  Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants. , 2005, ILAR journal.

[20]  Y. Shoenfeld,et al.  Guillain-Barré syndrome following hepatitis B vaccination. , 2004, Clinical and experimental rheumatology.

[21]  B. Franke,et al.  NOD2 mediates anti‐inflammatory signals induced by TLR2 ligands: implications for Crohn's disease , 2004, European journal of immunology.

[22]  B. Pulendran.  Modulating vaccine responses with dendritic cells and Toll‐like receptors , 2004, Immunological reviews.

[23]  Z. Popovic,et al.  Expression of Y7 Cross‐Reactive Idiotope on Human IgM Molecules , 2004, Immunological investigations.

[24]  A. Mari.  Is there a causative role for tetanus toxoid vaccination in the development of allergy-like symptoms and in the increasing prevalence of atopic diseases? , 2004, Medical hypotheses.

[25]  T. Aune,et al.  A Murine Locus on Chromosome 18 Controls NKT Cell Homeostasis and Th Cell Differentiation 1 , 2003, The Journal of Immunology.

[26]  A. Mantovani,et al.  Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. , 2003, Blood.

[27]  J. Kearney,et al.  CD9 Is a Unique Marker for Marginal Zone B Cells, B1 Cells, and Plasma Cells in Mice1 , 2002, The Journal of Immunology.

[28]  Ruslan Medzhitov,et al.  Control of adaptive immune responses by Toll-like receptors. , 2002, Current opinion in immunology.

[29]  A. Tobar,et al.  Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. , 2002, The Journal of clinical investigation.

[30]  A. Billiau,et al.  Modes of action of Freund’s adjuvants in experimental models of autoimmune diseases , 2001, Journal of leukocyte biology.

[31]  Andreas Radbruch,et al.  Oxidation of beta2-glycoprotein I (beta2GPI) by the hydroxyl radical alters phospholipid binding and modulates recognition by anti-beta2GPI autoantibodies , 2000, Thrombosis and haemostasis.

[32]  B. Haines,et al.  Germline diversity of the expressed BALB/c VhJ558 gene family. , 2001, Molecular immunology.

[33]  J. Farrar,et al.  NEUROLOGICAL ASPECTS OF TROPICAL DISEASE: Tetanus , 2000 .

[34]  Y. Shoenfeld,et al.  Vaccination and autoimmunity-'vaccinosis': a dangerous liaison? , 2000, Journal of autoimmunity.

[35]  E. B. Lindblad.  Freund's Adjuvants , 2000 .

[36]  Derek T. O'Hagan,et al.  Vaccine adjuvants : preparation methods and research protocols , 2000 .

[37]  D. Isenberg,et al.  Animal models of the antiphospholipid syndrome. , 1999, Rheumatology.

[38]  R. Abuknesha,et al.  Cross-Reactivity between the Rheumatoid Arthritis-Associated Motif EQKRAA and Structurally Related Sequences Found inProteus mirabilis , 1999, Infection and Immunity.

[39]  K. Seidl,et al.  Predominant VH genes expressed in innate antibodies are associated with distinctive antigen-binding sites. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Radulovic,et al.  Human monoclonal IgM DJ binds to ssDNA and human commensal bacteria. , 1999, Human antibodies.

[41]  R. Abuknesha,et al.  Cross-reactivity between the rheumatoid arthritis-associated motif EQKRAA and structurally related sequences found in Proteus mirabilis. , 1999, Infection and immunity.

[42]  K. Ahmadi,et al.  Antibodies to Klebsiella pneumoniae lipopolysaccharide in patients with ankylosing spondylitis. , 1998, British journal of rheumatology.

[43]  E. Bertram,et al.  Chemical chaperones enhance superantigen and conventional antigen presentation by HLA-DM-deficient as well as HLA-DM-sufficient antigen-presenting cells and enhance IgG2a production in vivo. , 1998, Journal of immunology.

[44]  C. Hunter,et al.  IL-1α and TNF-α Are Required for IL-12-Induced Development of Th1 Cells Producing High Levels of IFN-γ in BALB/c But Not C57BL/6 Mice , 1998, The Journal of Immunology.

[45]  C. Hunter,et al.  IL-1 alpha and TNF-alpha are required for IL-12-induced development of Th1 cells producing high levels of IFN-gamma in BALB/c but not C57BL/6 mice. , 1998, Journal of immunology.

[46]  R. Jankov,et al.  Expression of Y7 Idiotope on IgM Molecules from Cord Sera , 1997 .

[47]  U. Galili.  Alpha-Galactosyl (Anti-Gal) Autoantibodies , 1996 .

[48]  T. Odrljin,et al.  Immunochemical characterisation of a murine monoclonal anti-idiotypic antibody. , 1992, Journal of immunoassay.

[49]  A. Henschen,et al.  Limited proteolysis of tetanus toxin. Relation to activity and identification of cleavage sites. , 1991, European journal of biochemistry.

[50]  K. Kovacina,et al.  Detection of cross-reacting idiotypes in sera of lymphoma patients by inverse monoclonal radioimmunoassay. , 1990, Acta haematologica.

[51]  F. Alt,et al.  Developmentally regulated and strain-specific expression of murine VH gene families , 1988, The Journal of experimental medicine.

[52]  E. A. Brown.  Freund's adjuvants. , 1969, Review of allergy.